OCT 03, 2014 12:00 AM PDT

More Than 700 Biosimilar Therapies in Pipelines

WRITTEN BY: Ilene Schneider
It is rare to see a new business segment emerge in any market, but this is what is happening within the biopharmaceutical development industry, according to a new report from Thomson Reuters BioWorld, the premier biopharmaceutical news service.

There are currently 700 follow-on biologics therapies moving through pipelines with many already approved and 245 biopharma companies and institutes developing or already marketing follow-on biologics in markets throughout the world. Biosimilars are expected to account for approximately one quarter of the $100 billion worth of sales stemming from off-patent biologics by the end of the decade, the report said.

South Korea is a notable standout in the race for global leadership in this space, and India anticipates biosimilars becoming the most important economic and therapeutic component of its already robust biopharma industry. The study-the culmination of BioWorld's research combined with key data and insights gathered from CortellisTM Competitive Intelligence and input from Thomson Reuters Life Sciences Professional Services, provides a comprehensive view of this emerging market with a listing of approved biosimilars, company and deal terms for more than 100 alliances, and an examination of global markets.

Key highlights from the report include:
* Big pharma and generics makers face a steep learning curve: While generic makers currently lead the pack, the expertise in this market is held by the biologics makers. New pure-play biosimilar makers funded by governments and private investors also have a strong presence in this arena.

* Biosimilars promise to deliver big savings: Typically offering 20 to 30 percent discounts from innovator biologics, biosimilars are expected to deliver $11 billion to $33 billion in savings across the European Union (EU) by 2020.

* Opportunities for smaller players: Start-ups working to make and sell biosimilars in emerging territories could be the "David" ticket to beat pharma "Goliaths" that dominate those realms.

* Lower-prices: Slow market uptake of biosimilars in the EU may not also hold true for the U.S. Unlike most of the EU, the U.S. will allow interchangeability, which is expected to speed adoption and lead to lower prices.

* A level playing field: The World Health Organization recently proposed a voluntary, global naming scheme that could level the playing field for biosimilars and their reference biologics.

* Accessible treatment: In many parts of the world, follow-ons offer new hope to patients who previously did not have access to pricey biologics, bringing the power of biologics for the first time to markets in Africa, Asia, Eastern Europe and Latin America.

"Rather than forgo the benefits of biologics, governments and payers are counting on biosimilars to dramatically change drug development and patient costs by reducing the price tag of important biologics and increasing access to life-saving drugs," said Jon Brett-Harris, managing director of Thomson Reuters Life Sciences. "For this to happen, biosimilars must deliver the power of the reference drugs at a price developing countries can afford and gain the confidence of the marketplace. They have to create their own market."
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
MAR 14, 2021
Genetics & Genomics
How Stress Increases the Risk of Preterm Birth
MAR 14, 2021
How Stress Increases the Risk of Preterm Birth
Preterm birth is when a baby is born before the 37th week of pregnancy. The liver, lungs & brain undergo a crucial devel ...
MAR 15, 2021
Cell & Molecular Biology
Newly-ID'ed Organelle May Play a Role in Cancer Metastasis
MAR 15, 2021
Newly-ID'ed Organelle May Play a Role in Cancer Metastasis
Cells are packed full of organelles and molecules like proteins floating in a liquid known as cytoplasm. In recent years ...
MAR 21, 2021
Cell & Molecular Biology
A Model of Early Human Development is Created
MAR 21, 2021
A Model of Early Human Development is Created
Scientists now have a new way to investigate the processes underlying human development, diseases that may arise during ...
MAR 25, 2021
Cardiology
Improved Triage Method to Get STEMI Patients from Door to Treatment
MAR 25, 2021
Improved Triage Method to Get STEMI Patients from Door to Treatment
A heart attack is an incredibly sudden and dangerous cardiac event that requires quick action for a successful recovery. ...
MAR 23, 2021
Coronavirus
A Mother-to-Fetus COVID-19 Transmission Has Devastating Consequences
MAR 23, 2021
A Mother-to-Fetus COVID-19 Transmission Has Devastating Consequences
A pregnant woman infected with the pandemic virus SARS-CoV-2 passed the virus on to her unborn child through the placent ...
MAR 25, 2021
Health & Medicine
THC Detectable in Mother's Breast Milk for Six Weeks
MAR 25, 2021
THC Detectable in Mother's Breast Milk for Six Weeks
The effect on babies whose mothers consume cannabis while they are in the womb or breastfeeding is inconsistent and not ...
Loading Comments...